Clinical trials
Oligometastatic Prostate Cancer clinical trials
Below are recruiting oligometastatic prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 44 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07686016Recruiting
Radiation therapy for prostate cancer that has spread to a few spots
This trial studies the use of radiation to the prostate and to all visible spots where cancer has spread, in men who have up to 10 small areas of spread when first diagnosed. The goal is to see if this approach can help control the cancer.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT07015138Recruiting
Comparing two radiation approaches for prostate cancer that has spread a little
This trial is testing whether giving radiation to all spots of cancer that show up on a PSMA PET scan works better than giving radiation only to the main tumor in the prostate. It is for men whose prostate cancer has spread to a few other places (up to 10 spots).
Beijing, Beijing MunicipalityAges 18–85 - NCT07090148RecruitingPhase 1
Vaccine plus immunotherapy for prostate cancer that has returned
This trial tests a combination of a DNA vaccine (pTVG-HP) and an immunotherapy drug (nivolumab) along with targeted radiation or ablation of remaining cancer spots. It is for men whose prostate cancer has come back after surgery but hasn't spread widely.
Madison, WisconsinAges 18 years+ - NCT01834001Recruiting
MRI checks how prostate cancer responds to radiation
This study uses MRI scans to see how prostate cancer changes after radiation treatment, especially in the local (prostate-area) response. It may help doctors better judge treatment effectiveness and plan care more precisely.
Bethesda, MarylandAges 18–120 - NCT07717268RecruitingPhase 2
Stereotactic Radiation Plus New Hormone Therapy for Prostate Cancer
This trial tests a targeted, high-dose radiation therapy (SBRT) plus a newer hormone drug (abiraterone or enzalutamide) for men whose prostate cancer has spread to a small number of spots (5 or fewer) and is no longer controlled by standard hormone therapy.
Zaragoza, AragonAges Any age - NCT05939414RecruitingPhase 3
Lutetium prostate cancer treatment for limited PSMA-spread
This Phase 3 trial compares a targeted radiation medicine called lutetium (177Lu) vipivotide tetraxetan versus watchful waiting in people with prostate cancer that has spread to only a few spots. The goal is to see if the treatment can better control the cancer when scans show a small amount of PSMA-positive metastases.
Fayetteville, ArkansasAges 18–100 - NCT05183074Recruiting
MRI-guided focused radiation for prostate cancer
This trial tests a newer way to plan and deliver radiation for prostate cancer using real-time MRI guidance. It may help by aiming high-dose treatment precisely while treating nearby disease and (in some cases) limited metastatic spots.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06150417RecruitingPhase 2
Study of extra radiation for prostate cancer spread to few spots
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
Cleveland, OhioAges 18 years+ - NCT06758882RecruitingPhase 2
Surgery with or without apalutamide for high-risk prostate cancer that has spread a little
This trial tests whether adding the drug apalutamide before and after surgery helps men with high-risk prostate cancer that has spread to a few spots (seen on a special PET scan). You would also receive standard hormone therapy.
Torino, ToAges 18–80 - NCT06259123RecruitingPhase 2
PSMA Radiotherapy Before Prostate Cancer Surgery
This trial tests a radioactive drug (PSMA-RLT) given before surgery for prostate cancer that has spread to a few spots. It aims to see if this treatment can stop the cancer from growing further.
ViennaAges 18–75 - NCT05209243Recruiting
Treating limited-spread prostate cancer with radiation plus hormone therapy
This trial studies whether adding focused radiation (SBRT) to hormone therapy can control prostate cancer that has spread to only a few places. It aims to help people with early “oligometastatic” prostate cancer by improving disease control while limiting treatment side effects.
MadridAges Any age - NCT04498767Recruiting
Radiation to treat a few metastatic spots in rare cancers
This trial studies whether stereotactic (high-precision) radiation given in a few sessions can control rare cancers that have spread to a small number of sites. It aims to help by treating all known spots while keeping side effects manageable.
AnderlechtAges 18 years+ - NCT06201078RecruitingPhase 2
Second radiation for prostate cancer that returns locally
This trial tests a second round of precise, high-dose radiation (stereotactic body radiotherapy) for men whose prostate cancer has come back only in the prostate after their first radiation treatment. It aims to control the recurrence with fewer side effects.
GliwiceAges 18–80 - NCT07142551RecruitingPhase 2
Testosterone priming with darolutamide for metastatic prostate cancer
This trial tests whether giving a high dose of testosterone before standard hormone therapy can help the treatment work longer for men with prostate cancer that has spread. You would receive testosterone injections for a short time, then a hormone blocker (darolutamide) along with continued testosterone shots.
Baltimore, MarylandAges 18 years+ - NCT06439888RecruitingPhase 1/Phase 2
Immune cells plus radiation for limited-stage cancer spread
This trial tests whether giving immune-supporting cells (lymphocytes) alongside focused radiation (SBRT) can help control limited cancer spread. People with 1 to 5 small tumors that can all be radiated within two weeks may be eligible.
LyonAges 18 years+ - NCT06655259RecruitingPhase 2
TURP with standard therapy for metastatic prostate cancer
This trial tests whether adding a surgery called TURP (transurethral resection of the prostate) to the usual hormone therapy and chemotherapy can help men with metastatic prostate cancer that has spread to lymph nodes, bone, or other organs. The surgery helps relieve urinary symptoms and may improve how well the cancer responds to treatment.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07210086RecruitingPhase 2
PET scans to guide radiation for limited metastatic prostate cancer
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
Duarte, CaliforniaAges 18 years+ - NCT07413523Recruiting
Radiation therapy plus standard care for urothelial cancer with limited spread
This trial tests whether adding targeted radiation therapy to standard drug treatment can help people with urothelial cancer that has spread to a few spots (up to 3 outside the brain). If you are starting your first or second round of systemic therapy, this study may be an option.
Rozzano, MilanAges 18 years+ - NCT06141070RecruitingPhase 3
Adding high-dose radiation to standard treatment for advanced lung cancer
This trial tests whether adding a high, focused dose of radiation to the usual first treatment (chemo and/or immunotherapy) can help people with non-small cell lung cancer that has spread to a limited number of spots (up to 5). The goal is to see if this approach improves how well the treatment works.
GothenburgAges 18 years+ - NCT04883671Recruiting
SBRT to treat a few spots of adenoid cystic cancer
This trial tests whether focused radiation (SBRT) can help control adenoid cystic carcinoma that has spread to a small number of places (oligometastatic disease). If you qualify, the study will treat up to 1–5 metastatic spots that doctors think can be safely targeted, to help control the cancer locally.
San Francisco, CaliforniaAges 18 years+
Hear when a new Oligometastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for oligometastatic prostate cancer?
- Yes. Clin2 currently lists 44 recruiting oligometastatic prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a oligometastatic prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a oligometastatic prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.